UBS Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $437M | Buy |
7,200,449
+1,049,337
| +17% | +$61.2M | 0.07% | 301 |
|
|
2025
Q4 | $332M | Sell |
6,151,112
-4,505,646
| -42% | -$217M | 0.05% | 348 |
|
|
2025
Q3 | $481M | Sell |
10,656,758
-1,728,931
| -14% | -$80.7M | 0.08% | 243 |
|
|
2025
Q2 | $573M | Buy |
12,385,689
+2,753,268
| +29% | +$135M | 0.1% | 200 |
|
|
2025
Q1 | $587M | Buy |
9,632,421
+18,213
| +0.2% | +$1.06M | 0.11% | 183 |
|
|
2024
Q4 | $544M | Buy |
9,614,208
+1,982,741
| +26% | +$111M | 0.1% | 181 |
|
|
2024
Q3 | $395M | Buy |
7,631,467
+1,078,108
| +16% | +$50.6M | 0.09% | 226 |
|
|
2024
Q2 | $272M | Sell |
6,553,359
-1,063,674
| -14% | -$47.6M | 0.07% | 274 |
|
|
2024
Q1 | $413M | Buy |
7,617,033
+2,745,207
| +56% | +$140M | 0.1% | 189 |
|
|
2023
Q4 | $250M | Sell |
4,871,826
-2,048,229
| -30% | -$108M | 0.07% | 269 |
|
|
2023
Q3 | $402M | Buy |
6,920,055
+763,736
| +12% | +$46.8M | 0.14% | 140 |
|
|
2023
Q2 | $394M | Buy |
6,156,319
+170,841
| +3% | +$11.5M | 0.13% | 155 |
|
|
2023
Q1 | $415M | Sell |
5,985,478
-838,733
| -12% | -$59.2M | 0.15% | 131 |
|
|
2022
Q4 | $491M | Buy |
6,824,211
+1,359,771
| +25% | +$103M | 0.18% | 115 |
|
|
2022
Q3 | $388M | Sell |
5,464,440
-428,464
| -7% | -$31.1M | 0.17% | 116 |
|
|
2022
Q2 | $454M | Sell |
5,892,904
-508,349
| -8% | -$38.7M | 0.19% | 114 |
|
|
2022
Q1 | $467M | Sell |
6,401,253
-1,093,879
| -15% | -$73.4M | 0.16% | 133 |
|
|
2021
Q4 | $467M | Sell |
7,495,132
-22,933
| -0.3% | -$1.35M | 0.13% | 151 |
|
|
2021
Q3 | $445M | Buy |
7,518,065
+338,260
| +5% | +$22.3M | 0.14% | 151 |
|
|
2021
Q2 | $480M | Buy |
7,179,805
+1,224,518
| +21% | +$79.8M | 0.15% | 130 |
|
|
2021
Q1 | $376M | Sell |
5,955,287
-744,320
| -11% | -$46.3M | 0.12% | 167 |
|
|
2020
Q4 | $416M | Buy |
6,699,607
+635,824
| +10% | +$39.1M | 0.14% | 160 |
|
|
2020
Q3 | $366M | Buy |
6,063,783
+18,096
| +0.3% | +$1.09M | 0.14% | 155 |
|
|
2020
Q2 | $355M | Sell |
6,045,687
-1,799,488
| -23% | -$108M | 0.15% | 150 |
|
|
2020
Q1 | $437M | Sell |
7,845,175
-2,318,074
| -23% | -$142M | 0.21% | 112 |
|
|
2019
Q4 | $652M | Buy |
10,163,249
+3,538,088
| +53% | +$203M | 0.23% | 100 |
|
|
2019
Q3 | $336M | Sell |
6,625,161
-903,304
| -12% | -$42.5M | 0.13% | 165 |
|
|
2019
Q2 | $341M | Buy |
7,528,465
+2,080,097
| +38% | +$96.9M | 0.13% | 161 |
|
|
2019
Q1 | $260M | Sell |
5,448,368
-299,069
| -5% | -$14.9M | 0.11% | 192 |
|
|
2018
Q4 | $299M | Sell |
5,747,437
-2,369,608
| -29% | -$127M | 0.14% | 169 |
|
|
2018
Q3 | $504M | Buy |
8,117,045
+316,058
| +4% | +$18.8M | 0.2% | 118 |
|
|
2018
Q2 | $432M | Sell |
7,800,987
-89,990
| -1% | -$4.86M | 0.19% | 132 |
|
|
2018
Q1 | $499M | Sell |
7,890,977
-746,728
| -9% | -$48M | 0.22% | 109 |
|
|
2017
Q4 | $529M | Buy |
8,637,705
+1,074,384
| +14% | +$67.2M | 0.22% | 111 |
|
|
2017
Q3 | $482M | Sell |
7,563,321
-1,331,405
| -15% | -$77.7M | 0.22% | 105 |
|
|
2017
Q2 | $496M | Buy |
8,894,726
+1,364,066
| +18% | +$74.2M | 0.26% | 93 |
|
|
2017
Q1 | $410M | Sell |
7,530,660
-538,788
| -7% | -$29.6M | 0.22% | 104 |
|
|
2016
Q4 | $472M | Buy |
8,069,448
+482,331
| +6% | +$26.4M | 0.26% | 78 |
|
|
2016
Q3 | $409M | Buy |
7,587,117
+2,743,291
| +57% | +$176M | 0.24% | 88 |
|
|
2016
Q2 | $356M | Buy |
4,843,826
+30,121
| +0.6% | +$2.13M | 0.22% | 101 |
|
|
2016
Q1 | $308M | Sell |
4,813,705
-328,984
| -6% | -$20.7M | 0.21% | 109 |
|
|
2015
Q4 | $354M | Buy |
5,142,689
+1,068,512
| +26% | +$70.6M | 0.23% | 92 |
|
|
2015
Q3 | $241M | Sell |
4,074,177
-288,805
| -7% | -$18.3M | 0.17% | 133 |
|
|
2015
Q2 | $290M | Sell |
4,362,982
-90,460
| -2% | -$5.96M | 0.19% | 115 |
|
|
2015
Q1 | $287M | Buy |
4,453,442
+130,451
| +3% | +$8.17M | 0.2% | 117 |
|
|
2014
Q4 | $255M | Buy |
+4,322,991
| New | +$244M | 0.18% | 134 |
|
Other funds holding BMY
VCM
VPM
UBS Group's BMY Position: Q1 2026 in Review
UBS Group increased its Bristol-Myers Squibb (BMY) stake by 17% in Q1 2026, buying an estimated $61.2M and bringing the position to 7,200,449 shares worth $437M. The position accounts for 0.07% of the portfolio, ranked #301.
UBS Group first reported a position in BMY in Q4 2014 and has held it in 46 quarters since. The position peaked at $652M in Q4 2019. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- UBS Group held 7,200,449 shares of Bristol-Myers Squibb worth $437M as of Q1 2026.
- UBS Group bought 1,049,337 Bristol-Myers Squibb shares in Q1 2026, an estimated $61.2M.
- Bristol-Myers Squibb made up 0.07% of UBS Group's portfolio in Q1 2026, its #301 holding.
- UBS Group first reported a position in Bristol-Myers Squibb in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Bristol-Myers Squibb position peaked at $652M in Q4 2019.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.